Indo-Bangla Pharmaceuticals (DHA:IBP) EBITDA per Share: BDT (TTM As of . 20)


DHA:IBP Indo-Bangla Pharmaceuticals Ltd DHA:IBP
32 GF Score
Price BDT17.70
View Full Analysis

What is Indo-Bangla Pharmaceuticals EBITDA per Share?

Indo-Bangla Pharmaceuticals DHA:IBP -1.12% 32 EBITDA per Share is BDT as of . 20. GuruFocus rates DHA:IBP with a GF Score™ of 32/100. Among 814 Drug Manufacturers companies, Indo-Bangla Pharmaceuticals ranks worse than 122850% on this metric.

Indo-Bangla Pharmaceuticals's EBITDA per Share for the six months ended in . 20 was BDT0.00. Indo-Bangla Pharmaceuticals does not have enough years/quarters to calculate its EBITDA per Share for the trailing twelve months (TTM) ended in . 20.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for Indo-Bangla Pharmaceuticals's EBITDA per Share or its related term are showing as below:

DHA:IBP's 3-Year EBITDA Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.9
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

Indo-Bangla Pharmaceuticals's EBITDA for the six months ended in . 20 was BDT0.00 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.


Indo-Bangla Pharmaceuticals  (DHA:IBP) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


Indo-Bangla Pharmaceuticals EBITDA per Share Related Terms


Indo-Bangla Pharmaceuticals EBITDA per Share Historical Data

* Premium members only.

The historical data trend for Indo-Bangla Pharmaceuticals's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo-Bangla Pharmaceuticals EBITDA per Share Chart

Indo-Bangla Pharmaceuticals Annual Data
Trend
EBITDA per Share

Indo-Bangla Pharmaceuticals Semi-Annual Data
EBITDA per Share
DHA:IBP
32GF Score
Indo-Bangla Pharmaceuticals Ltd DHA:IBP
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indo-Bangla Pharmaceuticals EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Indo-Bangla Pharmaceuticals's EBITDA per Share for the fiscal year that ended in . 20 is calculated as

EBITDA per Share(A: . 20 )
=EBITDA/Shares Outstanding (Diluted Average)
=/0
=N/A

Indo-Bangla Pharmaceuticals's EBITDA per Share for the quarter that ended in . 20 is calculated as

EBITDA per Share(Q: . 20 )
=EBITDA/Shares Outstanding (Diluted Average)
=/0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of BDT mean?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a EBITDA per Share of BDT as of . 20. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Indo-Bangla Pharmaceuticals and its competitors. According to the industry distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 814 companies in the Drug Manufacturers industry.
Is Indo-Bangla Pharmaceuticals' EBITDA per Share too high?
Indo-Bangla Pharmaceuticals' current EBITDA per Share is BDT. Based on the distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 814 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' EBITDA per Share compare to ?
According to the Drug Manufacturers industry distribution chart, Indo-Bangla Pharmaceuticals ranks #999999 out of 814 companies for EBITDA per Share. This places Indo-Bangla Pharmaceuticals in the lower half of its industry. The industry median EBITDA per Share is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Drug Manufacturers company?
The median EBITDA per Share among Drug Manufacturers companies is 8.90, based on 814 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on Indo-Bangla Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA per Share is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo-Bangla Pharmaceuticals's current EBITDA per Share is BDT. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current EBITDA per Share of BDT. The current EBITDA per Share is BDT. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current EBITDA per Share is BDT as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indo-Bangla Pharmaceuticals Business Description

Comparable Companies
Address Ahmed Akbar Sobhan Road, Block B, Plot No. 183, 6th Floor, Bashundhara R/A, Baridhara, Dhaka, BGD, 1229
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score

Get the complete analysis for DHA:IBP

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT17.70
Price